Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03294551 · ClinicalTrials.gov registry record · NA
HPV Centralized R/R RCT #2 - New York State
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 37,003
- Enrollment target
NCT03294551: Completed NA study, sponsored by University of California, Los Angeles.
NCT03294551 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 37,003 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2537% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03294551, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 37,003 participants
- Enrollment target
Study Summary
The work done in this trial builds off of the work previously conducted by this same research group in clinicaltrials.gov ID: NCT03057379. Due to some changes in study design, protocol, and cohort of interest, a new registration was warranted. The overarching goal of this study is to evaluate the effectiveness, cost-effectiveness, and sustainability of utilizing statewide immunization information systems (IISs) to conduct centralized reminder recall (R/R) to improve human papillomavirus (HPV) vaccination rates among adolescents 11-14 years of age. The latest recommendations from the ACIP, as of February 2017, modified the vaccination schedule for the HPV series for eligible adolescents ages 11-14. Adolescents who receive dose #1 between the ages of 11 and 14 are now eligible for their second and final dose 6-12 months after their initial dose. Despite U.S. guidelines for vaccinating all adolescents starting at age 11 with the HPV vaccine, in 2012 only 53% of 13-17 year old females had \>1 dose and 35% had 3 doses; 21% of teen males had a vaccination. Modeling studies predict marked reduction in HPV associated cancers and in disparities in these cancers if high HPV vaccination rates can be achieved. With this new dosing schedule for adolescents, the research team proposes to conduct a randomized control trial (RCT) utilizing the capabilities of the State Immunization Information System (IIS), and create a HPV-specific R/R autodialer and text message to be delivered to the parents of patients ages 11-14 of randomly selected practices within New York State (excluding NYC). Upon conclusion of this trial, researchers will develop a toolkit for dissemination so that other state IIS systems may replicate these centralized reminder recall procedures.
Primary Outcome
Receipt and documentation of the initial dose of the vaccine within the series as recorded in the NYSIIS database. Investigators are allowing 5 months after the initial reminder recall was sent as the timeline of attributing vaccination status to the intervention
Interventions
- BEHAVIORAL HPV Vaccine Reminder Recall - Autodialer
- BEHAVIORAL HPV Vaccine Reminder Recall - Texting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37,003 participants |
| Start Date | 2017-10-27 |
| Est. Completion | 2019-11-05 |
| Phase | NA |
What the finished NCT03294551 record still lists
NCT03294551 is an interventional study that assigns participants to a tested intervention. Its 37,003 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2537% higher).
The record links to 0 conditions, and to 2 interventions - of which HPV Vaccine Reminder Recall - Autodialer is the first listed.
NCT03294551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03294551 about?
NCT03294551 is a clinical study titled "HPV Centralized R/R RCT #2 - New York State". The work done in this trial builds off of the work previously conducted by this same research group in clinicaltrials.gov ID: NCT03057379. Due to some changes in study design, protocol, and cohort of interest, a new registration was warranted. The overarching goal of this study is to evaluate the e...
What is the current status of trial NCT03294551?
This trial is currently completed. It is a NA study. The enrollment target is 37,003 participants. The study started on 2017-10-27. Estimated completion is 2019-11-05.
What interventions are being tested in trial NCT03294551?
The interventions under investigation include: HPV Vaccine Reminder Recall - Autodialer (BEHAVIORAL), HPV Vaccine Reminder Recall - Texting (BEHAVIORAL).
Who is sponsoring clinical trial NCT03294551?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03294551's enrollment target sits among peer trials
37,003 7th of 2000 higher than 1,994 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796505 · 37,122 participants · NA
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI